New Silk Road Investment Pte LTD Bei Gene, Ltd. Transaction History

New Silk Road Investment Pte LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$121.11 - $216.05 $411,774 - $734,570	-3,400 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $498,168 - $916,504	3,400 New	3,400 $641,000
Q3 2020 Nov 09, 2020	SELL	$189.18 - $286.44 $2.13 Million - $3.22 Million	-11,250 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$123.9 - $195.41 $1.54 Million - $2.43 Million	-12,450 Reduced 52.53%	11,250 $2.12 Million
Q1 2020 May 11, 2020	BUY	$121.84 - $173.19 $2.89 Million - $4.1 Million	23,700 New	23,700 $2.92 Million
Q4 2019 Feb 10, 2020	SELL	$115.78 - $208.34 $2 Million - $3.6 Million	-17,258 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$120.61 - $148.29 $12.8 Million - $15.7 Million	-106,117 Reduced 86.01%	17,258 $2.11 Million
Q2 2019 Jul 31, 2019	BUY	$113.99 - $146.86 $14.1 Million - $18.1 Million	123,375 New	123,375 $15.3 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of New Silk Road Investment Pte LTD, based on Form 13F filings with the SEC.

Stay updated on New Silk Road Investment Pte LTD with notifications on news.